Precision Peptide Company Inc

As of April 30, 2026, Precision Peptide Company Inc carries a market capitalization of 21.26M, placing it among publicly traded companies globally. Its enterprise value stands at 20.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of April 30, 2026, Precision Peptide Company Inc has 45.71M shares outstanding.

These figures are as of April 30, 2026. The price-to-sales ratio is 146.91, and the price-to-book ratio stands at 20.23.

These figures are as of April 30, 2026. The EV/Sales ratio of 198.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 20.48M versus a market cap of 21.26M, with the gap driven by net debt and cash on the balance sheet.

As of April 30, 2026, Precision Peptide Company Inc maintains a current ratio of 3.37, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended April 30, 2026. Return on assets (ROA) is negative at -631.45, reflecting losses generated across the asset base. Inventory turnover of 2.05 indicates how many times Precision Peptide Company Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended April 30, 2026, Precision Peptide Company Inc generated 103,205.00 in revenue and converted that into -5.63M in net income, yielding earnings per share of -0.17. EBITDA reached -5.51M, while operating income came in at -3.31M.

These figures are as of April 30, 2026. Total book value stands at 1.05M, with working capital of 1.05M providing operational flexibility.

Precision Peptide Company Inc produced -3.56M in operating cash flow over the twelve months ended April 30, 2026.

Over the twelve months ended April 30, 2026, Precision Peptide Company Inc posted a gross margin of 51.53, reflecting its pricing power and cost economics. The operating margin of -3,204.56 and net profit margin of -5,452.85 provide insight into operational efficiency.

These figures cover the twelve months ended April 30, 2026. Free cash flow yield is negative at -23.46: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.88, meaning Precision Peptide Company Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Precision Peptide Company Inc's most recent stock split took place on February 18, 2025 with a 6:1 split ratio.

As of April 30, 2026, Precision Peptide Company Inc has an Altman Z-Score of 12.60, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.